✨Exciting to see clinical efficacy of peripheral #CB1R antagonism with #monlunabant. It will expand armamentarium for #obesity with an oral 💊therapy and a different mechanism than incretins ( #GLP1 #GIP)💉

⚡️Similar efficacies in all tested oral doses encourage testing lower doses to optimize safety.

Peripheral CB1 receptor blockade for treatment of obesity The endocannabinoid system—comprising cannabinoid receptors (CB1 and CB2), lipid-derived ligands, and metabolic enzymes—plays a major role in regulating energy homoeostasis.1 CB1 receptors are abundan...

Kishore M Gadde & colleagues comment on:
Peripheral CB1 receptor blockade for treatment of obesity www.thelancet.com/journals/lan...
#monlunabant #obesity #metabolic #syndrome

#MedSky #EndoSky

The implications of this trial, combined with existing evidence, suggest that #monlunabant has potential as a novel treatment option for people with #obesity and #metabolic #syndrome, if a safe and effective therapeutic window can be established www.thelancet.com/journals/lan...

#MedSky #EndoSky

Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial Participants receiving monlunabant showed statistically significant and clinically meaningful weight loss compared with those receiving placebo for all tested doses. Only slightly greater weight loss ...

New—Efficacy and safety of #monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial thelancet.com/journals/lan...
#obesity #MetabolicSyndrome

#MedSky #EndoSky